Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

被引:116
|
作者
Higashihara, Eiji [2 ]
Torres, Vicente E. [1 ]
Chapman, Arlene B. [3 ]
Grantham, Jared J. [4 ]
Bae, Kyongtae [5 ]
Watnick, Terry J. [6 ]
Horie, Shigeo [7 ]
Nutahara, Kikuo [2 ]
Ouyang, John [8 ]
Krasa, Holly B. [8 ]
Czerwiec, Frank S. [8 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Coll Med, Rochester, MN 55905 USA
[2] Kyorin Univ, Sch Med, Tokyo, Japan
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Teikyo Univ, Sch Med, Tokyo 173, Japan
[8] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2011年 / 6卷 / 10期
基金
美国国家卫生研究院;
关键词
DIETARY-PROTEIN RESTRICTION; BLOOD-PRESSURE CONTROL; VOLUME PROGRESSION;
D O I
10.2215/CJN.03530411
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses of primary and secondary end points included LMM using all subject data and mixed model repeated measures (MMRM) of change from baseline at each year. Pearson correlation tested the association between log-TKV and eGFR changes. Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls 1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m(2)) were similar. Control TKV increased 5.8% versus 1.7%/yr for tolvaptan (P < 0.001, estimated ratio of geometric mean 0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined: -2.1 versus -0.71 ml/min per 1.73 m(2)/yr (P = 0.01, LMM group difference 1.1 ml/min per 1.73 m(2)/yr [95% confidence interval 0.24 to 1.9]). Sensitivity analyses including withdrawn subjects were similar, whereas MMRM analyses were significant at each year for TKV and nonsignificant for eGFR. Increasing TKV correlated with decreasing eGFR (r = -0.21, P < 0.01). Conclusion ADPKD cyst growth progresses more slowly with tolvaptan than in historical controls, but AEs are common. Clin J Am Soc Nephrol 6: 2499-2507, 2011. doi: 10.2215/CJN.03530411
引用
收藏
页码:2499 / 2507
页数:9
相关论文
共 50 条
  • [31] EFFECT OF TOLVAPTAN ON A BODYWATER BALANCE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Makita, Minoru
    Nishio, Saori
    Kondo, Keiichi
    Kawashima, Keisuke
    Ishikawa, Yozo
    Hattanda, Fumihiko
    Kusunoki, Yoshihiro
    Matsuoka, Naoko
    Yamamoto, Junya
    Nakagaki, Tasuku
    Takeda, Hiroshi
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 93 - 93
  • [32] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
  • [33] Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu, Fei
    Feng, Chunyue
    Shen, Huijun
    Fu, Huaidong
    Mao, Jianhua
    KIDNEY DISEASES, 2021, 7 (05) : 343 - 349
  • [34] Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
    Anderegg, Manuel A.
    Dhayat, Nasser A.
    Sommer, Grit
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Fuster, Daniel G.
    KIDNEY MEDICINE, 2020, 2 (02) : 162 - 171
  • [35] Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Inoue, Reiko
    Nishi, Hiroshi
    Inoue, Daisuke
    Honda, Kenjiro
    Nangaku, Masaomi
    KIDNEY360, 2020, 1 (08): : 2020 - 745
  • [36] Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
    Gilbert, Rodney D.
    Evans, Hazel
    Olalekan, Kazeem
    Nagra, Arvind
    Haq, Mushfequr R.
    Griffiths, Mark
    PEDIATRIC NEPHROLOGY, 2017, 32 (05) : 893 - 896
  • [37] Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
    Kunizawa, Kyohei
    Hoshino, Junichi
    Mizuno, Hiroki
    Suwabe, Tatsuya
    Sumida, Keiichi
    Kawada, Masahiro
    Yamanouchi, Masayuki
    Sekine, Akinari
    Hayami, Noriko
    Hiramatsu, Rikako
    Hasegawa, Eiko
    Sawa, Naoki
    Takaichi, Kenmei
    Shibata, Shigeru
    Ubara, Yoshifumi
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2018, 8 (01): : 62 - 69
  • [38] Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Sekine, Akinari
    Hoshino, Junichi
    Fujimaru, Takuya
    Suwabe, Tatsuya
    Mizuno, Hiroki
    Kawada, Masahiro
    Hiramatsu, Rikako
    Hasegawa, Eiko
    Yamanouchi, Masayuki
    Hayami, Noriko
    Mandai, Shintaro
    Chiga, Motoko
    Kikuchi, Hiroaki
    Ando, Fumiaki
    Mori, Takayasu
    Sohara, Eisei
    Uchida, Shinichi
    Sawa, Naoki
    Takaichi, Kenmei
    Ubara, Yoshifumi
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (09) : 745 - 751
  • [39] CLINICAL EFFICACY OF TREATMENT WITH TOLVAPTAN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Martins Munoz, Judith
    Tarragon, Blanca
    De Lorenzo, Alberto
    Espinel, Laura
    Teresa Naya, Maria
    Cubas, Alfonso
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I13 - I13
  • [40] Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Response
    Erickson, Kevin F.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (02) : 143 - 143